Research Analysts’ Weekly Ratings Changes for Waystar (WAY)

A number of research firms have changed their ratings and price targets for Waystar (NASDAQ: WAY):

• 7/31/2026 – Waystar had its “overweight” rating reaffirmed by KeyCorp.
• 7/31/2026 – Waystar had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $39.00 price target on the stock.
• 7/30/2026 – Waystar had its price target lowered by UBS Group AG from $37.00 to $33.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Waystar had its price target lowered by Wells Fargo & Company from $36.00 to $33.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Waystar had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $33.00 price target on the stock.
• 7/20/2026 – Waystar was given a new $34.00 price target by UBS Group AG.
• 7/20/2026 – Waystar had its “buy” rating reaffirmed by Citigroup Inc..
• 7/1/2026 – Waystar is now covered by KeyCorp. They set an “overweight” rating and a $30.00 price target on the stock.
• 7/1/2026 – Waystar is now covered by KeyCorp. They set an “overweight” rating and a $30.00 price target on the stock.
• 6/24/2026 – Waystar was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.

Waystar (NASDAQ:WAY) is a leading provider of cloud-based revenue cycle management and payment solutions for healthcare organizations. The company’s unified platform streamlines the entire financial continuum of patient care, from eligibility verification and claim submission to payment reconciliation and patient billing. By automating key processes and improving claim accuracy, Waystar helps providers reduce administrative overhead, accelerate cash flow and enhance overall revenue performance.

At the core of Waystar’s offering is a SaaS-based architecture that integrates seamlessly with existing electronic health record (EHR) systems and payer networks.